Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Denosumab injection (Xgeva®)	TA265 - Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Deucravacitinib	TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis
Dexamethasone (Ozurdex®) 700mcg intravitreal implant	TA229 - Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamfetamine tablets	TA98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents	ESCAs and additional advice in relation to age of patient and CCG
Dexamfetamine tablets	TA98 - Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents	ESCAs and additional advice in relation to age of patient and CCG
Diltiazem cream (ANOHEAL)	Advice - Chronic anal fissure: 2% topical diltiazem hydrochloride	For patients unable to tolerate or with contraindications to GTN. Very expensive high relative cost.
Dimethyl fumarate	TA320 - Dimethyl fumarate for treating relapsing-remitting multiple sclerosis TA475 - Dimethyl fumarate for treating moderate to severe plaque psoriasis
Diprosalic ointment	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Potent potency
Diprosalic scalp application	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Potent potency
Dipyridamole M/R capsules	TA210 - Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.